At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 10, 2026 at 08:17 ET
Oncolytics Biotech announced positive preclinical results combining its lead candidate pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The study showed pelareorep activity was maintained in the presence of RAS inhibition without antagonism, supporting further evaluation of the combination to potentially deepen responses and delay resistance. This is an early-stage, non-clinical data readout with no financial terms or near-term catalyst disclosed, making it a modest positive signal for the pipeline but not a material event for the stock.
- Preclinical study evaluated pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
- Pelareorep activity was maintained in the presence of RAS inhibition without evidence of antagonism.
- Greatest tumor reductions were observed in the RAS inhibitor and combination groups during initial every-other-day dosing.
- Incremental activity from pelareorep became less evident after transitioning to weekly dosing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access